GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » Market Cap

Astellas Pharma (TSE:4503) Market Cap : 円2,609,099 Mil (As of Mar. 04, 2025)


View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Astellas Pharma's share price for the quarter that ended in Dec. 2024 was 円1534.5. Astellas Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 1,790 Mil. Therefore, Astellas Pharma's market cap for the quarter that ended in Dec. 2024 was 円2,746,939 Mil.

Astellas Pharma's quarterly market cap increased from Jun. 2024 (円2,845,877 Mil) to Sep. 2024 (円2,947,899 Mil) but then declined from Sep. 2024 (円2,947,899 Mil) to Dec. 2024 (円2,746,939 Mil).

Astellas Pharma's annual market cap declined from Mar. 2022 (円3,491,540 Mil) to Mar. 2023 (円3,383,305 Mil) and declined from Mar. 2023 (円3,383,305 Mil) to Mar. 2024 (円2,949,651 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Astellas Pharma's Enterprise Value for Today is 円3,312,108 Mil.


Astellas Pharma Market Cap Historical Data

The historical data trend for Astellas Pharma's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Market Cap Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,103,900.88 3,153,857.06 3,491,540.33 3,383,304.73 2,949,651.15

Astellas Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,022,974.40 2,949,651.15 2,845,877.40 2,947,899.42 2,746,939.14

Competitive Comparison of Astellas Pharma's Market Cap

For the Drug Manufacturers - General subindustry, Astellas Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Market Cap distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Market Cap falls into.



Astellas Pharma Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Astellas Pharma's Market Cap for the fiscal year that ended in Mar. 2024 is calculated as

Market Cap (A: Mar. 2024 )=Share Price (A: Mar. 2024 )*Shares Outstanding (EOP) (A: Mar. 2024 )
=円1645*1793.101
=円2,949,651

Astellas Pharma's Market Cap for the quarter that ended in Dec. 2024 is calculated as

Market Cap (Q: Dec. 2024 )=Share Price (Q: Dec. 2024 )*Shares Outstanding (EOP) (Q: Dec. 2024 )
=円1534.5*1790.120
=円2,746,939

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma  (TSE:4503) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Astellas Pharma Market Cap Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines